Eperisone

DKSH Continues Strengthening its Healthcare Own Brands Business With the Acquisition of two Brands From Eisai

Retrieved on: 
Monday, November 7, 2022

With the acquisition, DKSH continues its strategy to expand its Healthcare Own Brands portfolio and to grow in Asia Pacific.

Key Points: 
  • With the acquisition, DKSH continues its strategy to expand its Healthcare Own Brands portfolio and to grow in Asia Pacific.
  • DKSH already markets these products for Eisai in most of the nine Asian markets and with the acquisition now becomes full brand owner.
  • Bijay Singh, Head Business Unit Healthcare at DKSH, commented: This acquisition is another indicator of our commitment to growing our Own Brands portfolio.
  • The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices.

Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH

Retrieved on: 
Monday, November 7, 2022

Eisai believes that this divestiture agreement will accelerate the pursuit of the best marketing mix in the ALA Region.

Key Points: 
  • Eisai believes that this divestiture agreement will accelerate the pursuit of the best marketing mix in the ALA Region.
  • Under the terms of the agreement, Eisai will receive a contractual up-front payment, and also plan to supply the products.
  • Eisai will retain its manufacturing rights to and continue to distribute the products in countries such as Japan, China and South Korea.
  • *Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines (Myonal only), Singapore, Taiwan (Merislon only), Thailand
    DKSH's purpose is to enrich people's lives.